Researchers at Stanford have created human induced pluripotent stem cells (hiPSCs) derived from adult human dermal fibroblasts exposed to an environmental factor.
Mature pancreatic islets are the gold standard for transplantation-based approaches for islet replacement in type 1 and type 3c diabetes mellitus (T1D and T3cD), but this feature is offset by the scarcity of human cadaveric pancreas donors.
Stanford inventors have identified a treatment regimen that allows expansion of cardiomyocytes (CMs) derived from human induced pluripotent stem cells in vitro.